Kite Pharma, a subsidiary of Gilead, has unveiled an innovative method for analyzing individual lentiviral vector particles. This development aims to significantly improve the characterization of future in vivo CAR T therapy products compared to traditional methods like Western blotting.
Understanding the Importance of Viral Vectors
“The virus is central to our product, and we seek to gain the deepest possible understanding of it,” states Kristen Kellar, a scientist in the analytical development team at Kite. This approach reflects the growing recognition of the importance of viral vectors in gene and cell therapies, particularly in the context of enveloped viruses such as lentiviruses.
Priti Hegde, PhD, Kite’s senior vice president of research and development, emphasizes the urgency of robust characterization methods in this emerging field. “As we explore the best practices for characterizing our products, we are committed to developing methods that provide deeper insights,” she adds.
The New Flow Virometry Technique
Kellar explains that the new technique leverages flow virometry, enabling the analysis of individual particles as they pass through a detector. This method allows for precise characterization of various attributes, including particle size and surface proteins.
One of the significant advantages of this approach is its ability to map protein distribution accurately. For example, if one vector particle possesses ten times the amount of a specific protein compared to another, traditional Western blot methods would yield an average value that obscures these differences. In contrast, flow virometry preserves the unique characteristics of each particle, thereby enhancing the understanding of their distinct roles.
Enhanced Instrumentation for Deeper Insights
While flow virometry has been utilized previously, advancements in nanoparticle analysis instruments have elevated the method’s capability for deeper characterization. Kellar notes, “Recent technological advancements give us confidence that we can detect all particles accurately, ensuring they are the correct size.” Moreover, the ability to stain surface proteins adds another layer of detail that was previously difficult to achieve.
This enhanced capability not only improves the understanding of viral vector characteristics but also facilitates more informed decisions throughout the development process.
Application in Product Development
Kite Pharma plans to integrate this novel technology at various stages of product development, including during the final phases to ensure consistency across batches. Kellar mentions that they are also exploring quantitation bead sets that will allow for precise quantification of viral proteins present on the vector surface.
Hegde highlights the significance of these developments, stating, “Given the early stage of in vivo cell therapy, it is exciting to see clinical proof of concept emerging. Our next challenge is to scale our processes robustly and effectively.”
Conclusion
Kite Pharma’s new cytometry technique represents a significant leap forward in the analysis of viral vectors, enhancing the characterization and understanding of these crucial components in gene therapies. As the field continues to evolve, this pioneering approach promises to accelerate the development and refinement of CAR T therapies and other innovative treatments.
- Key Takeaways:
- Kite Pharma introduces a novel flow virometry technique for analyzing lentiviral vectors.
- This method allows detailed characterization of individual viral particles, enhancing understanding of their properties.
- The technology aims to improve consistency in product development and support scaling efforts in the emerging field of cell therapy.
- Enhanced instrumentation and staining capabilities provide deeper insights into viral vector characteristics, paving the way for more effective gene therapies.
Read more → www.genengnews.com